Search Results

June 3, 2022

Phase 3 SHINE Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma

Primary results from the first frontline Phase 3 study of a Bruton’s tyrosine kinase inhibitor in MCL to be presented as late-breaking data at the 2022 ASCO Annual Meeting and also published in The New England Journal of Medicine

Innovative Medicine

June 1, 2022

New Data Show Patients Treated with First-in-Class TREMFYA® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years

Adult patients with active psoriatic arthritis experienced persistent multi-domain efficacy and a safety profile consistent with that seen in plaque psoriasis Further analyses show TREMFYA provided sustained improvements across measures of health-related quality of life

Innovative Medicine

May 31, 2022

Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA

Studies spanning industry-leading hematologic malignancies portfolio and pipeline with new research in solid tumor therapies to highlight precision medicine and targeted therapy strategies

Innovative Medicine

May 26, 2022

European Commission Grants Conditional Approval of CARVYKTI® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

In the pivotal clinical study CARTITUDE-1, 98 percent of patients with relapsed or refractory multiple myeloma responded to a one-time treatment with ciltacabtagene autoleucel and 80 percent of patients who responded experienced a stringent complete response [1]

Innovative Medicine

May 25, 2022

Johnson & Johnson to Provide Webcast Fireside Chat on Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting and the Janssen Oncology Strategy and Portfolio

Innovative Medicine

May 24, 2022

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022

New data show proportions of patients treated with TREMFYA who achieved clinical-biomarker response ranged from 47.5-66.7 percent across dose groups in the Phase 2 GALAXI 1 study Other data presented demonstrate the long-term safety profile of STELARA® (ustekinumab) in bio-naïve and bio-failure patients living with inflammatory bowel disease

Innovative Medicine

May 23, 2022

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)

COMPASS open label extension study results support the long-term use of XARELTO® plus aspirin for vascular protection in patients with chronic CAD and/or PAD XATOA registry provides further evidence of the benefit of DPI for CAD and/or PAD patients at high risk of cardiovascular (CV) events

Innovative Medicine

May 18, 2022

New Data Show TREMFYA® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab

In vitro studies suggest TREMFYA neutralizes IL-23 where it is produced, enhancing the ability of TREMFYA to prevent local activation of cells that drive inflammation TREMFYA is the first fully human IL-23 inhibitor indicated for adults with moderate to severe plaque psoriasis and adults with active psoriatic arthritis

Innovative Medicine

May 18, 2022

New Janssen Campaign Developed by and for the LGBTQ+ Community Inspires Action and Empathy for People Living with Depression

Depression Looks Like Me Provides a Safe Space to Elevate the Experiences of the Community and Provide Resources for Adults Living with Hard-to-Treat Forms of Depression

Innovative Medicine

May 5, 2022

MPAACT Consortium Unites Industry and Academia to Establish Measurable Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Drug Development

Validated Measurable Residual Disease Assays are Critical for the Rapid Development of Future Novel Therapeutics for Patients with Acute Myeloid Leukemia

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine